Targeting CDKN3 in cervical cancer

Bibliography

• Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-19
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65
   PubMed Web of Science ®Google Scholar
• Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368-83
   PubMedGoogle Scholar
• de Sanjose S, Quint W, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2:868-78
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of therandomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99
   PubMed Web of Science ®Google Scholar
• Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin 2011;7:161-9
   PubMed Web of Science ®Google Scholar
• Cuzick J. Long-term cervical cancer prevention strategies across the globe. Gynecol Oncol 2010;117:S11-14
   Google Scholar
• Rana MM, Huhtala H, Apter D, et al. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: cancer registry-based follow-up. Int J Cancer 2013;132(12):2833-8
   PubMedGoogle Scholar
• Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24
   PubMedGoogle Scholar
• Natunen K, Lehtinen J, Namujju P, et al. Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol 2011;2011:675858
   PubMedGoogle Scholar
• Hwang SJ, Shroyer KR. Biomarkers of cervical dysplasia and carcinoma. J Oncol 2012;2012:507286
   PubMedGoogle Scholar
• Ferlay J, Shin HR, Bray F, et al. GLOBOCAN v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France; 2008. Available from: http://globocan.iarc.fr
   Google Scholar
• Andrae B, Andersson TM, Lambert PC, et al. Screening and cervical cancer cure: population based cohort study. BMJ 2012;344:e900
   Google Scholar
• Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011;3:623-36
   PubMed Web of Science ®Google Scholar
• Knight Z, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010;10:130-7
   PubMed Web of Science ®Google Scholar
• Sawyer TK, Wu JC, Sawyer JR, et al. Protein kinase inhibitors: breakthrough medicines and the next generation. Expert Opin Investig Drugs 2013;22(6):675-8
   PubMed Web of Science ®Google Scholar
• Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev 2012;32:166-215
   PubMed Web of Science ®Google Scholar
• Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012;12:553-63
   PubMed Web of Science ®Google Scholar
• Espinosa AM, Alfaro A, Roman-Basaure E, et al. Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One 2013;8(2):e55975
   PubMed Web of Science ®Google Scholar
• Medina-Martínez I, Barrón V, Roman-Basaure E, et al. Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: a genome-wide follow-up study. PLoS One 2014;9(5):e97842
   Google Scholar
• Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005;331(2):269-91
   PubMedGoogle Scholar
• Buitrago-Pérez A, Garaulet G, Vázquez-Carballo A, et al. Molecular signature of HPV-induced carcinogenesis: pRb, p53 and gene expression profiling. Curr Genomics 2009;10(1):26-34
   PubMedGoogle Scholar
• Teissier S, Ben Khalifa J, Mori M, et al. New E6/P63 pathway, together with a strong E7/E2F mitotic pathway, modulates the transcriptome in cervical cancer cells. J Virol 2007;81(17):9368-76
   PubMedGoogle Scholar
• Thierry F, Benotmane M, Demeret C, et al. A genomic approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. Cancer Res 2004;64(3):895-903
   PubMedGoogle Scholar
• Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550-60
   PubMed Web of Science ®Google Scholar
• Patel D, McCance DJ. Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6- and E7-expressing keratinocytes. J Virol 2010;84:10956-64
   PubMedGoogle Scholar
• Demetrick DJ, Matsumoto S, Hannon GJ, et al. Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). Cytogenet Cell Genet 1995;69:190-2
   PubMedGoogle Scholar
• Gyuris J, Golemis E, Chertkov H. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 1993;75:791-803
   PubMed Web of Science ®Google Scholar
• Nalepa G, Barnholtz-Sloan J, Enzor R, et al. The tumor suppressor CDKN3 controls mitosis. J Cell Biol 2013;201(7):997-1012
   PubMedGoogle Scholar
• Chhavi SM, Singh S, Negi MP, et al. Expression profiling of G2/M phase regulatory proteins in normal, premalignant and malignant uterine cervix and their correlation with survival of patients. J Cancer Res Ther 2010;6(2):167-71
   PubMedGoogle Scholar
• Tsai CJ, Sulman EP, Eifel PJ, et al. Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecol Oncol 2013;131(3):645-9
   PubMedGoogle Scholar
• Shen SN, Wang LF, Jia YF, et al. Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer. Diagn Pathol 2013;8:69
   PubMed Web of Science ®Google Scholar
• Wu Z, Peng X, Li J, et al. Constitutive activation of nuclear factor kB contributes to cystic fibrosis transmembrane conductance regulator expression and promotes human cervical cancer progression and poor prognosis. Int J Gynecol Cancer 2013;23(5):906-15
   PubMedGoogle Scholar
• MacDermed DM, Khodarev NN, Pitroda SP, et al. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics 2010;3:16
   PubMed Web of Science ®Google Scholar
• Li T, Xue H, Guo Y. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer. Oncol Rep 2014;31(4):1825-31
   PubMedGoogle Scholar
• Yu Y, Jiang X, Schoch BS, et al. Aberrant splicing of cyclin-dependent kinase–associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res 2007;67(1):130-8
   PubMedGoogle Scholar
• Lee SW, Reimer CL, Fang L, et al. Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol Cell Biol 2000;20(5):1723-32
   PubMedGoogle Scholar
• Lee J, Sung CO, Lee EJ, et al. Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene. PLoS ONE 2012;7(4):e34456
   Google Scholar
• Lin WR, Lai MW, Yeh CT. Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth. Oncol Rep 2013;29(3):903-10
   PubMedGoogle Scholar
• Xing C, Xie H, Zhou L. Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation. Biochem Biophys Res Commun 2012;420(1):29-35
   PubMedGoogle Scholar
• Yeh CT, Lu SC, Chen TC. Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. Cancer Res 2000;60(17):4697-700
   PubMedGoogle Scholar
• Yeh CT, Lu SC, Chao CH. Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. Biochem Biophys Res Commun 2003;305(2):311-14
   PubMedGoogle Scholar
• Lai MW, Chen TC, Pang ST. Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells. Urol Oncol 2012;30(6):871-8
   PubMedGoogle Scholar
• Hunter KD, Thurlow JK, Fleming J, et al. Divergent routes to oral cancer. Cancer Res 2006;66(15):7405-13
   PubMedGoogle Scholar
• Lens SM, Voest EE, Medema RH. Shared and separate functions of pololike kinases and aurora kinases in cancer. Nat Rev Cancer 2010;10:825-41
   PubMed Web of Science ®Google Scholar
• Berumen J, Ordoñez RM, Lazcano E, et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case–control study. J Natl Cancer Inst 2001;93(17):1325-30
   PubMedGoogle Scholar
• Ordóñez RM, Espinosa AM, Sánchez-González DJ, et al. Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6/E7 oncogene transcription. J Gen Virol 2004;85(6):1433-44
   PubMedGoogle Scholar
• Chen Y, Miller C, Mosher R, et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res 2003;63:1927-35
   PubMed Web of Science ®Google Scholar
• Narayan G, Bourdon V, Chaganti S, et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 2007;46:373-84
   PubMed Web of Science ®Google Scholar
• Rosty C, Sheffer M, Tsafrir D, et al. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 2005;24:7094-104
   PubMed Web of Science ®Google Scholar
• Gius D, Funk MC, Chuang EY, et al. Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res 2007;67:7113-23
   PubMedGoogle Scholar
• Zhai Y, Kuick R, Nan B, et al. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res 2007;67:10163-72
   PubMed Web of Science ®Google Scholar
• Pyeon D, Newton M, Lambert P, et al. Fundamental differences in cell cycle deregulation in human papillomavirus–positive and human papillomavirus–negative head/neck and cervical cancers. Cancer Res 2007;67(10):10163-72
   PubMedGoogle Scholar
• Biewenga P, Buist M, Moerland P, et al. Gene expression in early stage cervical cancer. Gynecol Oncol 2008;108(3):520-6
   PubMedGoogle Scholar
• Scotto L, Narayan G, Nandula S, et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 2008;47(9):755-65
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26
   PubMed Web of Science ®Google Scholar
• Slodkowska EA, Ross JS. MammaPrint™ 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 2009;9(5):417-22
   PubMed Web of Science ®Google Scholar
• Saghatchian M, Mook S, Pruneri G, et al. Additional prognostic value of the 70-gene signature (MammaPrint< sup>®</sup>) among breast cancer patients with 4–9 positive lymph nodes. Breast 2013;22(5):682-90
   PubMed Web of Science ®Google Scholar
• Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 2012;85(2):187-200
   PubMedGoogle Scholar
• Julien SG, Dubé N, Hardy S, et al. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 2011;11(1):35-49
   PubMed Web of Science ®Google Scholar
• Hardy S, Tremblay ML. Protein tyrosine phosphatases: new markers and targets in oncology? Curr Oncol 2008;15(1):5
   PubMedGoogle Scholar
• Ríos P, Nunes-Xavier CE, Tabernero L, et al. Dual-specificity phosphatases as molecular targets for inhibition in human disease. Antioxid Redox Signal 2014;20(14):2251-73
   PubMedGoogle Scholar
• Mullauer FB, Kessler JH, Medema JP. Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 2010;21(3):215-27
   PubMed Web of Science ®Google Scholar
• Mertens-Talcott SU, Noratto GD, Li X. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10. Mol Carcinog 2013;52(8):591-602
   PubMed Web of Science ®Google Scholar